Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis.

Wei, Qige; Wang, Hui; Zhao, Jianglin; Luo, Zhongping; Wang, Chufeng; Zhu, Chunmei; Su, Na; Zhang, Shengzhao

Wei, Qige; Wang, Hui; Zhao, Jianglin; Luo, Zhongping; Wang, Chufeng; Zhu, Chunmei; Su, Na; Zhang, Shengzhao.

Afiliação

Wei Q; Department of Pharmacy, Karamay Central Hospital/Karamay Hospital of Xinjiang Uygur Autonomous Region People's Hospital, Karamay, China.
Wang H; Xinjiang Clinical Research Center for Precision Medicine of Digestive System Tumor, Karamay, China.
Zhao J; Xinjiang Key Laboratory of Clinical Genetic Testing and Biomedical Information, Karamay, China.
Luo Z; Department of Pharmacy, Karamay Central Hospital/Karamay Hospital of Xinjiang Uygur Autonomous Region People's Hospital, Karamay, China.
Wang C; Xinjiang Clinical Research Center for Precision Medicine of Digestive System Tumor, Karamay, China.
Zhu C; Xinjiang Key Laboratory of Clinical Genetic Testing and Biomedical Information, Karamay, China.
Su N; Department of Pharmacy, Karamay Central Hospital/Karamay Hospital of Xinjiang Uygur Autonomous Region People's Hospital, Karamay, China.
Zhang S; Xinjiang Clinical Research Center for Precision Medicine of Digestive System Tumor, Karamay, China.

Front Pharmacol ; 14: 1237234, 2023.

Article em En | MEDLINE | ID: mdl-37614310

Palavras-chave

Janus kinase inhbitors; all-cause mortality; cardiovascular safety; major cardiovascular adverse events; network meta-analysis; rheumathoid arthritis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Systematic_reviews Idioma: En Revista: Front Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google